Determinants of imminent fracture risk in postmenopausal women with osteoporosis

por Barron, R. L., Oster, G., Grauer, A., Crittenden, D. B., Weycker, D.
Publicado 2020

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

por Siris, E. S., Simon, J. A., Barton, I. P., McClung, M. R., Grauer, A.
Publicado 2007

Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures

por Weycker, D., Edelsberg, J., Barron, R., Atwood, M., Oster, G., Crittenden, D. B., Grauer, A.
Publicado 2017

Risk of subsequent fracture after prior fracture among older women

por Balasubramanian, A., Zhang, J., Chen, L., Wenkert, D., Daigle, S. G., Grauer, A., Curtis, J. R.
Publicado 2018

Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis

por Bonafede, M. M., Shi, N., Bower, A. G., Barron, R. L., Grauer, A., Chandler, D. B.
Publicado 2015

Association between telemedicine use and diabetes risk factor assessment and control in a primary care network

por Grauer, A., Duran, A. T., Liyanage-Don, N. A., Torres-Deas, L. M., Metser, G., Moise, N., Kronish, I. M., Ye, S.
Publicado 2022

Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis

por Silverman, S. L., Wang, A., Cheng, L., Yang, Y., Libanati, C., Geller, M., Grauer, A., Nevitt, M., Revicki, D., Viswanathan, H. N.
Publicado 2015

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

por Watts, N. B., Roux, C., Modlin, J. F., Brown, J. P., Daniels, A., Jackson, S., Smith, S., Zack, D. J., Zhou, L., Grauer, A., Ferrari, S.
Publicado 2011

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

por Kendler, D.L., Bone, H.G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S., Dinavahi, R.V., Libanati, C., Grauer, A.
Publicado 2019

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab

por McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., Grauer, A.
Publicado 2020